This is a multi-year aspirational guidance with no near-term hard catalyst. The projections are not backed by analyst consensus or near-term milestones. Monitor the 2026 quarterly results for signs of tracking toward the $90.5M revenue target. The CEO's insider buying provides some credibility, but the $14M market cap and historical volatility suggest caution. The LOI for a $11.5M revenue pharmacy network is a small near-term catalyst worth watching.
Price Chart
Executive Summary
Cosmos Health issued a multi-year financial guidance press release projecting revenue growth from $65.3M in 2025 to $200.6M by 2029 (207% increase, 32% CAGR), with gross margins expanding from 12.1% to 35.5% and a transition to profitability by 2027. The projections are aspirational and lack near-term hard catalysts, making this a low-credibility forward-looking narrative for a $14M market cap company.
Key Financial Metrics
Key Facts
- 2025A revenue of $65.3M, up 20% YoY; gross profit up 83%; gross margin expanded 418 bps; cash rose >10x to $3.5M
- 2026E revenue guided to ~$90.5M (+39% YoY); 2029E revenue projected at $200.6M (32% CAGR)
- Gross profit projected to rise 801% to $71.2M by 2029; gross margin from 12.1% to 35.5%
- Net income projected to improve from ($19.1M) loss in 2025 to $31.0M profit by 2029; profitability expected in 2027
- Adjusted EBITDA projected from ($3.4M) in 2025 to $44.2M by 2029
- Operating cash flow projected positive in 2027 at $11.9M, growing to $24.0M by 2029
- Cash projected to increase 18x to $62.9M by 2029; all convertible notes expected to be fully repaid by 2026
- CEO Greg Siokas purchased >3.3M shares in 2025 and continued buying in 2026
- LOI to acquire a pharmacy distribution network generating ~$11.5M in annual gross revenue
- Athens real estate portfolio estimated fair market value of ~$15M being evaluated for monetization
Financial Impact
Multi-year revenue growth from $65.3M to $200.6M (207%); gross profit from $7.9M to $71.2M (801%); net income improvement of $50.1M
Risk Factors
- Multi-year projections are inherently speculative and not guaranteed; execution risk is high for a $14M market cap company
- No near-term hard catalysts; the projections are aspirational and may not be achievable
- Company has history of losses ($19.1M net loss in 2025) and negative operating cash flow ($8.4M in 2025)
- Convertible debt overhang exists until full repayment by 2026; dilution risk remains
- Highly competitive nutraceutical and pharmaceutical distribution markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301211 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.2530 | awaiting T+20 | — | $0.2360 (−6.72%) |
Oct 16, 2026 11d ago | SC 13G/A | $0.3250 | awaiting T+20 | — | $0.2360 (−27.38%) |
Oct 9, 2026 18d ago | 8-K | $0.3496 | awaiting T+20 | — | $0.2360 (−32.49%) |
Sep 3, 2026 7w ago | Press Release | $0.2660 $0.4300 | ▼ −61.65% | ▼ −62.77% | $0.2360 (+11.28%) |
Aug 19, 2026 9w ago | Press Release | $0.1930 | awaiting T+20 | — | $0.2360 (−22.28%) |
Jul 20, 2026 14w ago | Press Release | $0.2303 $0.2050 | ▼ −10.99% | ▼ −15.11% | $0.2360 (+2.48%) |
Jul 17, 2026 14w ago | Press Release | $0.2348 $0.2179 | ▼ −7.20% | ▼ −11.64% | $0.2360 (+0.51%) |
Jul 16, 2026 14w ago | Press Release | $0.2807 $0.2065 | ▼ −26.43% | ▼ −30.05% | $0.2360 (−15.92%) |
Jul 15, 2026 14w ago | Press Release | $0.2785 $0.2071 | ▼ −25.64% | ▼ −27.98% | $0.2360 (−15.26%) |
Jul 14, 2026 15w ago | Press Release | $0.3071 $0.2198 | ▼ −28.43% | ▼ −30.92% | $0.2360 (−23.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers